Zoetis Inc. is the world’s largest dedicated animal health company, specializing in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostics, genetic tests, biodevices, and digital technologies for animals. The company serves veterinarians, livestock producers, farmers, and pet owners in more than 100 countries, helping improve the health and well-being of companion animals and livestock. [1]

• Company Name: Zoetis Inc.
• Founded: 1952 (as the animal health business of Pfizer)
• Incorporated as Zoetis: 2012
• Public Listing: 2013 (NYSE: ZTS)
• Headquarters: Parsippany
• Industry: Animal Health / Veterinary Pharmaceuticals
• Stock Exchange: New York Stock Exchange (NYSE: ZTS)
• CEO: Kristin Peck
• Employees: Approximately 14,500 worldwide (2025)
• Annual Revenue: Approximately US$9.5 billion (2025) [2]

Zoetis traces its roots back to 1952, when Pfizer established its animal health division to develop veterinary medicines and vaccines.

In July 2012, Pfizer incorporated Zoetis as an independent company. In February 2013, Pfizer completed the initial public offering (IPO) of Zoetis, and later that year fully separated the business by exchanging its remaining ownership with shareholders.

Since becoming independent, Zoetis has expanded through continuous investment in research, acquisitions, and new product development, becoming the global leader in animal health. [3]

The name Zoetis (pronounced zō-EH-tis) originates from the Greek root “zoe”, meaning life. The name reflects the company’s mission of improving animal health through science and innovation. [4]

Purpose

To nurture our world and humankind by advancing care for animals.

Vision

To be the most trusted and valued animal health company, shaping the future of animal care through innovation, customer focus, and purpose-driven colleagues. [5]

Zoetis researches, develops, manufactures, and markets products for preventing, diagnosing, and treating diseases in animals.

Its portfolio includes:

• Vaccines
• Prescription medicines
• Parasiticides
• Dermatology treatments
• Pain management
• Sedation products
• Anti-infectives
• Diagnostic instruments
• Laboratory diagnostics
• Genetic testing
• Precision animal health technologies
• Digital veterinary solutions
• Biopharmaceuticals (including monoclonal antibody therapies) [6]

Zoetis develops products for eight primary animal groups:

Companion Animals

• Dogs
• Cats
• Horses

Livestock

• Beef cattle
• Dairy cattle
• Swine (pigs)
• Poultry
• Sheep
• Fish (aquaculture) [7]

Zoetis markets products across seven major categories:

• Parasiticides
• Vaccines
• Dermatology
• Anti-infectives
• Pain and Sedation
• Other Pharmaceuticals
• Animal Health Diagnostics [8]

Research and development is one of Zoetis’ core strengths.

The company invests heavily in:

• Veterinary pharmaceuticals
• Vaccine development
• Monoclonal antibodies
• Diagnostic technologies
• Artificial intelligence for diagnostics
• Precision animal health
• Genomics
• Data-driven disease prediction

Approximately 1,700 employees work in research and development across multiple global research centers. [9]

Zoetis operates approximately 21 manufacturing facilities worldwide that produce:

• Vaccines
• Pharmaceuticals
• Diagnostics
• Biological products

These facilities supply products to over 100 countries. [10]

Zoetis operates in:

• North America
• Latin America
• Europe
• Middle East
• Africa
• Asia-Pacific

Its products are sold in 100+ countries, supported by a global workforce and commercial organization. [11]

Zoetis organizes its business into two major segments:

Companion Animal

Products for:

• Dogs
• Cats
• Horses

This segment contributes approximately 70% of company revenue.

Livestock

Products for:

• Cattle
• Swine
• Poultry
• Fish
• Sheep

This segment contributes approximately 30% of revenue. [12]

Some of Zoetis’ best-known veterinary products include:

• Apoquel® – treatment for allergic itch in dogs
• Cytopoint® – monoclonal antibody for canine atopic dermatitis
• Simparica® – flea and tick protection
• Simparica Trio® – flea, tick, heartworm, and intestinal parasite prevention
• Librela® – osteoarthritis pain treatment for dogs
• Solensia® – osteoarthritis pain treatment for cats
• Draxxin® – antibiotic for cattle and swine
• Excede®
• ProHeart®
• Poulvac® vaccines
• Vanguard® vaccines [13]

Zoetis maintains a leading position in animal health through:

• Broad and diversified product portfolio
• Strong investment in research and development
• Global manufacturing and distribution network
• Trusted relationships with veterinarians
• Advanced diagnostics and digital health solutions
• Leadership in companion animal therapeutics
• Long history of veterinary innovation [14]

Zoetis emphasizes:

• Customer focus
• Innovation
• Integrity
• Collaboration
• Inclusion
• Scientific excellence
• Animal welfare
• Sustainability [15]

The company supports initiatives in:

• Animal welfare
• Responsible use of medicines
• Environmental sustainability
• Community engagement
• Diversity and inclusion
• Ethical business practices
• Employee development [16]

Zoetis is the world’s leading dedicated animal health company, with a history spanning nearly 75 years. Originally part of Pfizer, it became an independent public company in 2013 and has since built a broad portfolio of veterinary medicines, vaccines, diagnostics, and digital technologies. Serving veterinarians, livestock producers, and pet owners in more than 100 countries, Zoetis focuses on advancing animal care through science, innovation, and global collaboration, with a strong emphasis on both companion animals and livestock. [17]

1. About Zoetis | Zoetis
2. Annual Report
3. Zoetis at a Glance | Zoetis
4. Zoetis – Global Animal Health Company | Zoetis
5. Zoetis Inc. – Investor Relations
6. Zoetis Inc. – Investor Relations
7. zts-20251231
8. Our Company | Zoetis Philippines | Zoetis
9. Home | Zoetis
10. zoetis.com
11. History of Zoetis | Zoetis
12. Zoetis – Executive Team | Zoetis
13. About Us | Zoetis